Therapeutic Asset Ratings
498 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Bacitracin
FMT
Assaf Harofeh MC
N/A
D
(30)
Bacitracin
Metabolic Syndrome (MetS)
Catholic University of the Sacred Heart
N/A
D
(30)
Bacitracin
Obesity Type 2 Diabetes Mellitus
Eighth Affiliated Hospital, Sun Yat-sen University
N/A
D
(30)
Bacitracin
Recurrent C. Difficile (rCDI)
Catholic University of the Sacred Heart
N/A
D
(30)
Bacitracin
Ulcerative Colitis (UC)
Catholic University of the Sacred Heart
N/A
D
(30)
Bacitracin
Weight Loss
Assaf Harofeh MC
N/A
D
(30)
BLEOMYCIN
Anti-CD30
Helwan University
N/A
D
(30)
BLEOMYCIN
Brentuximab
Helwan University
N/A
D
(30)
BLEOMYCIN
Dacarbazine
Helwan University
N/A
D
(30)
BLEOMYCIN
Doxorubicin
Helwan University
N/A
D
(30)
BLEOMYCIN
Frontline
Helwan University
N/A
D
(30)
BLEOMYCIN
SKIN NEOPLASMS
Institute of Oncology Ljubljana
N/A
D
(30)
BLEOMYCIN
Vinblastine
Helwan University
N/A
D
(30)
DEXTROSE
Frozen Shoulder
Rizki Darmawan
N/A
D
(30)
DEXTROSE
Anterior Disc Displacement
Cairo University
N/A
D
(30)
DEXTROSE
Chronic Pain Syndrome
National and Kapodistrian University of Athens
N/A
D
(30)
DEXTROSE
Clicking Tinnitus
Cairo University
N/A
D
(30)
DEXTROSE
Gastroparesis
Karaman Training and Research Hospital
N/A
D
(30)
DEXTROSE
Hemiplegic Shoulder Pain
Istanbul Physical Medicine Rehabilitation Training and Research Hospital
N/A
D
(30)
DEXTROSE
Hyperinsulinism
University of Colorado, Denver
N/A
D
(30)
DEXTROSE
Hypogonadotropic Hypogonadism
University of Colorado, Denver
N/A
D
(30)
DEXTROSE
Idiopathic Scoliosis
National Taiwan University Hospital
N/A
D
(30)
DEXTROSE
Infertility Disorder
University of Colorado, Denver
N/A
D
(30)
DEXTROSE
Injection Site
Cairo University
N/A
D
(30)
DEXTROSE
Internal Derangement
Cairo University
N/A
D
(30)
Showing 326 to 350 of 498 assets
Previous
Page 14 of 20
Next